Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Thursday, March 19, 2026 · pelthos therapeutics, inc.

AI Briefing

ZELSUVMI net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million for the period from the launch in July 2025 through December 31, 2025.
Total revenue including licensing revenue was $16.8 million for 2025.
No further financial details were provided.